Disc Medicine, Inc. (IRON)
75.14
-0.97
(-1.27%)
USD |
NASDAQ |
Nov 20, 16:00
75.16
+0.02
(+0.03%)
After-Hours: 20:00
Disc Medicine Enterprise Value : 2.280B for Nov. 20, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 20, 2026 | 2.280B |
| November 19, 2026 | 2.318B |
| November 18, 2026 | 2.390B |
| November 17, 2026 | 2.335B |
| November 16, 2026 | 2.336B |
| November 13, 2026 | 2.468B |
| November 12, 2026 | 2.593B |
| November 11, 2026 | 2.741B |
| November 10, 2026 | 2.647B |
| November 09, 2026 | 2.516B |
| November 06, 2026 | 2.426B |
| November 05, 2026 | 2.409B |
| November 04, 2026 | 2.594B |
| November 03, 2026 | 2.513B |
| November 02, 2026 | 2.415B |
| October 30, 2026 | 2.500B |
| October 29, 2026 | 2.577B |
| October 28, 2026 | 2.591B |
| October 27, 2026 | 2.464B |
| October 26, 2026 | 2.377B |
| October 23, 2026 | 2.256B |
| October 22, 2026 | 2.276B |
| October 21, 2026 | 2.313B |
| October 20, 2026 | 2.448B |
| October 19, 2026 | 2.426B |
| Date | Value |
|---|---|
| October 16, 2026 | 1.573B |
| October 15, 2026 | 1.566B |
| October 14, 2026 | 1.531B |
| October 13, 2026 | 1.564B |
| October 12, 2026 | 1.714B |
| October 09, 2026 | 1.775B |
| October 08, 2026 | 1.725B |
| October 07, 2026 | 1.741B |
| October 06, 2026 | 1.759B |
| October 05, 2026 | 1.824B |
| October 02, 2026 | 1.870B |
| October 01, 2026 | 1.835B |
| September 30, 2026 | 1.906B |
| September 29, 2026 | 1.869B |
| September 28, 2026 | 1.833B |
| September 25, 2026 | 1.845B |
| September 24, 2026 | 1.891B |
| September 23, 2026 | 1.877B |
| September 22, 2026 | 1.969B |
| September 21, 2026 | 1.969B |
| September 18, 2026 | 2.009B |
| September 17, 2026 | 1.996B |
| September 16, 2026 | 1.972B |
| September 15, 2026 | 1.924B |
| September 14, 2026 | 1.986B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Agenus, Inc. | 453.57M |
| Amgen, Inc. | 276.45B |
| Anika Therapeutics, Inc. | 158.39M |
| BioCryst Pharmaceuticals, Inc. | 2.302B |
| Imunon, Inc. | 6.224M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -59.54M |
| Total Expenses (Quarterly) | 59.54M |
| EPS Diluted (Quarterly) | -1.530 |
| Earnings Yield | -8.43% |
| Normalized Earnings Yield | -8.434 |